Loading
A phase 1 trial of BPX-601 run by Regeneron Pharmaceuticals, now recruiting.
A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread is a phase 1 interventional study registered as NCT07543055 by Regeneron Pharmaceuticals, with 36 participants planned, started 2026-09-08. Conditions recorded: Prostate Cancer. Interventions recorded: BPX-601.
Shares BPX-601, Bellicum Pharmaceuticals, Regeneron, Prostate cancer and the tag pipeline.
Shares Regeneron, Prostate cancer and the tag pipeline.
Shares Bellicum Pharmaceuticals and the tag pipeline.
Shares Bellicum Pharmaceuticals and the tag pipeline.
Shares Bellicum Pharmaceuticals and the tag pipeline.
Shares Bellicum Pharmaceuticals and the tag pipeline.
Shares Regeneron and the tag pipeline.
Shares Bellicum Pharmaceuticals and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/